SCHEMBL24664459

SCHEMBL24664459

CC(C)c1ccc([C@@H](N)c2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.48
ADRA2C P18825 1/20 0.48
LMNA P02545 1/20 0.48
HIF1A Q16665 1/20 0.48
KDM4E B2RXH2 1/20 0.48
DPP4 P27487 2/20 0.48
F2 P00734 1/20 0.48
ALDH1A1 P00352 1/20 0.46
TAAR1 Q96RJ0 3/20 0.44
HTT P42858 1/20 0.41
ADRB2 P07550 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11875562 0.98 ALDH1A1 (0.50) ADRA2AADRA2CLMNAHIF1AKDM4E
Hydrochloric Acid SCHEMBL29820471 0.98 ALDH1A1 (0.50) ADRA2AADRA2CLMNAHIF1AKDM4E
Isopropylbenzene SCHEMBL7041369 0.87 TAAR1 (0.48) ADRA2AADRA2CLMNAHIF1AKDM4E
SCHEMBL11480062 0.87 DPP4 (0.61) ADRA2AADRA2CLMNAHIF1AKDM4E
SCHEMBL11478580 0.87 DPP4 (0.61) ADRA2AADRA2CLMNAHIF1AKDM4E
Isopropylbenzene SCHEMBL6568 0.84
Isopropylbenzene SCHEMBL87809 0.84 TAAR1 (0.50) ADRA2AADRA2CLMNAHIF1AKDM4E
Isopropylbenzene SCHEMBL11254813 0.84
Isopropylbenzene SCHEMBL8431863 0.84 TAAR1 (0.50) ADRA2AADRA2CLMNAHIF1AKDM4E
Isopropylbenzene SCHEMBL3672803 0.84 TAAR1 (0.50) ADRA2AADRA2CLMNAHIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059665-A1 DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed